Close X
Attorney Spotlight

How does Jordana Nelson's prior experience as a general counsel inform her work with firm clients? Read more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

The M&A Advisor Winner 2017The M&A Advisor announced the winners of the 16th Annual M&A Advisor Awards on Monday, November 13 at the 2017 M&A Advisor Awards. Bass, Berry & Sims was named a winner in the two categories related to the following deals:

M&A Deal of the Year (from $1B-$5B) – Acquisition of CLARCOR Inc. by Parker Hannifin Corporation

Corporate/Strategic Deal of the Year (over $1B) – Acquisition of BNC Bancorp by Pinnacle Financial Partners

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Regulation A+

It seems that lately there has been a noticeable uptick in Regulation A+ activity, including several recent Reg A+ securities offerings where the stock now successfully trades on national exchanges. In light of this activity, we have published a set of FAQs about Regulation A+ securities offerings to help companies better understand this "mini-IPO" offering process, as well as pros and cons compared to a traditional underwritten IPO.

Read now

Janelle Waack Comments on Supreme Court's Patent Ruling in Cuozzo

Modern Healthcare

Media Mentions

June 21, 2016

Bass, Berry & Sims attorney Janelle Waack provided comments for a Modern Healthcare article outlining the impact of the U.S. Supreme Court's decision in Cuozzo Speed Technologies v. Lee regarding the standard for reviewing patents, including those covering pharmaceuticals, medical devices, medical diagnostics and other healthcare technologies. The Supreme Court affirmed the Federal Circuit ruling allowing the U.S. Patent and Trademark Office's Patent Trial and Appeal Board to use the "broadest reasonable interpretation" claim construction standard in post-grant patent disputes. As Janelle points out in the article, "[h]ealth care companies need to invest in their patent drafting and prosecution upfront, understanding if you're challenged you'll likely be pulled into a PTAB proceeding where the rules are tilted in favor of the challenger."

The full article, "Supreme Court Decision a Win for Generic Drugmakers Fighting Patents," was published by Modern Healthcare on June 20, 2016, and is available online.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.